IMR Press / FBE / Volume 5 / Issue 3 / DOI: 10.2741/E670

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.


Use of autologous growth factors in aging tendon and chronic tendinopathy

Show Less
1 UR4 Aging, Stress and Inflammation Laboratory, University Pierre and Marie Curie University, 7, quai St-Bernard, 75252 Paris cedex 5, France
2 Clinique des Maussins, Groupe Maussin, 67 rue de romainville, 75019 Paris, France
3 Health for Health Foundation, Paris, France
4 Department of Rheumatology, Saint-Antoine Hospital, AP–HP, Pierre and Marie Curie University, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France
5 CNRS, UMR7622 , Pierre and Marie Curie University, 9 Quai St Bernard, Bat. C, 6E, Case 24, 75252 Paris Cedex 05, France

*Author to whom correspondence should be addressed.

Academic Editor: Ali Mobasheri

Front. Biosci. (Elite Ed) 2013, 5(3), 911–921;
Published: 1 June 2013
(This article belongs to the Special Issue Current trends in cartilage and mesenchymal stem cell biology)

Aging tendons or chronic tendinopathy are frequent conditions responsible for handicap in middleaged and aging populations. Current therapies fail to relieve handicap. Medical treatment can sometimes be efficient, but surgical procedures often fail to restore tendon function. Cell therapy with platelets, based on tendon histological modifications and the capacity of such tissue to respond to growth factors, is an ever-expanding field of clinical research. In the current review, we compare the histological properties of normal tendons, aging tendons and chronic tendinopathy. We explain the natural healing process of such tendons and the rationale for using, or not, autologous growth factors. We review current clinical studies exploring the effect of concentrated autologous growth factor injection in chronic lesions and attempt to explain why, to date, all clinical studies have demonstrated no effect of such therapies.

Aging Tendon
Chronic Tendinopathy
Platelet-Rich Plasma
Growth Factors
Back to top